GlyProVac has secured 4.0 mDKK in business angel investments. In addition, to the new group of investors, which count Allan Rosetzsky and Hans Christian Bukkehave, existing investor Niels Herman Kristiansen also took part in this private placement.
GlyProVac has secured 4.3 mDKK in a combination of equity investments from founders, SDI and business angel Niels Herman Kristiansen combined with a COVID-19 syndication loan from Growth fund Denmark.
GlyProVac ApS is founded and owned by Anders Boysen backed by Science Ventures Denmark (SVD) and personal investments from co-founder Ann Zahle Andersen and co-inventors of the original BEMAP technology Jakob Møller-Jensen, Martin Røssel Larsen and Giuseppe Palmisano. In 2018 GlyProVac ApS received equity funding from Syddansk Innovation (SDI) and Styrelsen for Institutioner og Uddannelsesstøtte (SIU).
Link to company at the Danish Central Business Register https://datacvr.virk.dk/enhed/virksomhed/39724758
474.000 DKK InnoBooster grant from the Danish Innovation Foundation for the five months development project titled ”Udvikling af bredspektret bakteriel vaccinekandidat – In vivo PoC valideret dyremodel”, The project will start in February 2022
2.25 mDKK Eurostars grant from EU and the Danish Innovation Foundation for the three-year development project titled “SVEET - Sugar-modified Vaccine Epitopes; Exploration and Translation”. The project starts April 2021.
400.000 DKK InnoBooster grant from the Danish Innovation Foundation for the nine months development project titled “Udvikling af bredspektret bakteriel vaccinekandidat – det vigtige valg af dyremodel”, The project started May 2020.
210.000 DKK COVID-19 InnoBooster additional grant from the Danish Innovation Foundation to extend the development project titled “GlyProVac - Bacterial glycoprotein antigens for vaccine development”. The project was successfully concluded in October 2020.
1 million DKK InnoBooster grant from the Danish Innovation Foundation for the two-year development project titled “GlyProVac - Bacterial glycoprotein antigens for vaccine development”. The project was successfully concluded in March 2020.
In 2014, during the early proof of principle phase at university of Southern Denmark, the GlyProVac project was supported with 2 mDKK from the Novo Pre-seed program.
In 2014 the internal PoC-board of University of Southern Denmark supported the early GlyProVac proof of concept project with 750.000 DKK.
Copyright © All Rights Reserved